To view a copy of this license, visit About this article Cite this article Ke, J., Liu, Y., Yang, J

Side-by-Side Comparison Feature Structure Melanotan 2 Cyclic 7-amino acid peptide Afamelanotide (MT-I) Linear 13-amino acid peptide PT-141 (Bremelanotide) Cyclic 7-amino acid derivative Feature Receptor focus Melanotan 2 MC1R + MC3R + MC4R + MC5R (non-selective) Afamelanotide (MT-I) MC1R-preferring PT-141 (Bremelanotide) MC3R/MC4R-preferring Feature Plasma half-life Melanotan 2 ~1-2 hours Afamelanotide (MT-I) ~0.8-1.7 hours PT-141 (Bremelanotide) ~2.7 hours Feature Main effect Melanotan 2 Tanning + sexual + appetite changes Afamelanotide (MT-I) Tanning and photoprotection PT-141 (Bremelanotide) Sexual arousal and desire Feature Tanning strength Melanotan 2 Strong Afamelanotide (MT-I) Strong PT-141 (Bremelanotide) Minimal Feature Sexual effect Melanotan 2 Strong in ED studies Afamelanotide (MT-I) Not primary PT-141 (Bremelanotide) Primary use case Feature Dosing Melanotan 2 Daily loading, then 1-2x weekly Afamelanotide (MT-I) Subcutaneous implant PT-141 (Bremelanotide) On-demand, max 1 per 24 hours Feature FDA status Melanotan 2 Not approved Afamelanotide (MT-I) Approved (Scenesse) for EPP PT-141 (Bremelanotide) Approved (Vyleesi) for low female sexual desire Feature Nausea burden Melanotan 2 High and dose-limiting Afamelanotide (MT-I) Lower in selective use PT-141 (Bremelanotide) Common, listed on label These three compounds share melanocortin ancestry, but they are not interchangeable

*Correspondence: Anton Luger, [email protected] This article was submitted to Pituitary Endocrinology, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Optimize your growth hormone levels naturally with physician-supervised CJC-1295 + Ipamorelin therapy